Pulmonary Hypertension in Saudi Arabia: A Single Center Experience

Overview

Journal Ann Thorac Med

Specialty Pulmonary Medicine

Date 2013 Jun 7

PMID 23741268

Citations 12

Authors

Esam H Alhamad

Joseph G Cal

Hussam F Alfaleh

Mostafa Q Alshamiri

Ahmad A AlBoukai

Suliman A Alhomida

Affiliations

Soon will be listed here.

Abstract

Context: Several international studies have described the epidemiology of pulmonary hypertension (PH). However, information about the incidence and prevalence of PH in Saudi Arabia is unknown.

Aims: To report cases of PH and compare the demographic and clinical characteristics of PH due to various causes in a Saudi population.

Methods: Newly diagnosed cases of PH [defined as mean pulmonary artery pressure >25 mmHg at right heart cauterization (RHC)] were prospectively collected at a single tertiary care hospital from January 2009 and June 2012. Detailed demographic and clinical data were collected at the time of diagnosis, along with hemodynamic parameters.

Results: Of the total 264 patients who underwent RHC, 112 were identified as having PH. The mean age at diagnosis was 55.8 ± 15.8 years, and there was a female preponderance of 72.3%. About 88 (78.6%) of the PH patients were native Saudis and 24 (21.4%) had other origins. Twelve PH patients (10.7%) were classified in group 1 (pulmonary arterial hypertension), 7 (6.2%) in group 2 (PH due to left heart disease), 73 (65.2%) in group 3 (PH due to lung disease), 4 (3.6%) in group 4 (chronic thromboembolic PH), and 16 (14.3%) in group 5 (PH due to multifactorial mechanisms). PH associated with diastolic dysfunction was noted in 28.6% of group 2 patients, 31.5% of group 3 patients, and 25% of group 5 patients.

Conclusions: These results offer the first report of incident cases of PH across five groups in Saudi Arabia.

Citing Articles

The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH.

Saleh K, Khan N, Dougherty K, Bodi G, Michalickova M, Mohammed S J Clin Med. 2023; 12(5).

PMID: 36902782 PMC: 10004663. DOI: 10.3390/jcm12051996.

Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions.

Tyagi R, Kant S, Pradhan A, Wakhlu A, Bajaj D, Bajpai J Can Respir J. 2021; 2021:1385322.

PMID: 34876943 PMC: 8645389. DOI: 10.1155/2021/1385322.

Pulmonary hypertension in the developing world: Local registries, challenges, and ways to move forward.

Idrees M, Butrous G, Mocumbi A, Sastry B, Ibrahim A, Alobaidallah K Glob Cardiol Sci Pract. 2020; 2020(1):e202014.

PMID: 33150158 PMC: 7590932. DOI: 10.21542/gcsp.2020.14.

Pulmonary hypertension: From an orphan disease to a global epidemic.

Butrous G Glob Cardiol Sci Pract. 2020; 2020(1):e202005.

PMID: 33150150 PMC: 7590934. DOI: 10.21542/gcsp.2020.5.

Chronic thromboembolic pulmonary hypertension in Saudi Arabia: preliminary results from the SAUDIPH registry.

AlDalaan A, Saleemi S, Weheba I, Abdelsayed A, Hammainen P, Aleid M ERJ Open Res. 2020; 6(2).

PMID: 32420315 PMC: 7211951. DOI: 10.1183/23120541.00218-2019.

References

Wanger J, Clausen J, Coates A, Pedersen O, Brusasco V, Burgos F . Standardisation of the measurement of lung volumes. Eur Respir J. 2005; 26(3):511-22. DOI: 10.1183/09031936.05.00035005. View

Bourbonnais J, Samavati L . Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008; 32(2):296-302. DOI: 10.1183/09031936.00175907. View

Jing Z, Xu X, Han Z, Wu Y, Deng K, Wang H . Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007; 132(2):373-9. DOI: 10.1378/chest.06-2913. View

Patel N, Lederer D, Borczuk A, Kawut S . Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007; 132(3):998-1006. DOI: 10.1378/chest.06-3087. View

Cabrol S, Souza R, Jais X, Fadel E, Ali R, Humbert M . Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2007; 26(4):357-62. DOI: 10.1016/j.healun.2006.12.014. View

Hurdman J, Condliffe R, Elliot C, Davies C, Hill C, Wild J . ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J. 2011; 39(4):945-55. DOI: 10.1183/09031936.00078411. View

McGoon M, Miller D . REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012; 21(123):8-18. PMC: 9487467. DOI: 10.1183/09059180.00008211. View

Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52(12):3792-800. DOI: 10.1002/art.21433. View

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View

10.

Jais X, DArmini A, Jansa P, Torbicki A, Delcroix M, Ghofrani H . Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(25):2127-34. DOI: 10.1016/j.jacc.2008.08.059. View

11.

Scadding J . Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961; 2(5261):1165-72. PMC: 1970202. DOI: 10.1136/bmj.2.5261.1165. View

12.

Peacock A, Murphy N, McMurray J, Caballero L, Stewart S . An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1):104-9. DOI: 10.1183/09031936.00092306. View

13.

Badesch D, Raskob G, Elliott C, Krichman A, Farber H, Frost A . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009; 137(2):376-87. DOI: 10.1378/chest.09-1140. View

14.

Fisher K, Serlin D, Wilson K, Walter R, Berman J, Farber H . Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006; 130(5):1481-8. DOI: 10.1378/chest.130.5.1481. View

15.

Lam C, Roger V, Rodeheffer R, Borlaug B, Enders F, Redfield M . Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009; 53(13):1119-26. PMC: 2736110. DOI: 10.1016/j.jacc.2008.11.051. View

16.

Le Pavec J, Girgis R, Lechtzin N, Mathai S, Launay D, Hummers L . Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011; 63(8):2456-64. DOI: 10.1002/art.30423. View

17.

Alhamad E, Idrees M, Alanezi M, AlBoukai A, Shaik S . Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients. Ann Thorac Med. 2010; 5(2):86-91. PMC: 2883203. DOI: 10.4103/1817-1737.62471. View

18.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

19.

MacIntyre N, Crapo R, Viegi G, Johnson D, van der Grinten C, Brusasco V . Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005; 26(4):720-35. DOI: 10.1183/09031936.05.00034905. View

20.

Hoeper M, Barbera J, Channick R, Hassoun P, Lang I, Manes A . Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S85-S96. DOI: 10.1016/j.jacc.2009.04.008. View